CRNX vs NBIX
CRNX: A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across multiple endocrine diseases. NBIX: A neuroscience-focused biopharmaceutical company commercializing specialized treatments for neurological and endocrine disorders while advancing a diverse pipeline of therapeutic modalities.
Side-by-side fundamentals
| Metric | CRNX | NBIX | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $83.52 | $176.41 | |
| Market cap as of 2026-08-02 | $8.8B | $17.9B | |
| P/E as of 2026-08-02 | n/a | 23.77 | |
| PEG as of 2026-08-02 | -0.47 | 0.27 | CRNX lower |
| Net margin as of 2026-08-02 | -2747.2% | +20.9% | NBIX higher |
| Gross margin as of 2026-08-02 | +86.0% | +98.0% | NBIX higher |
| Operating margin as of 2026-08-02 | -3020.3% | +23.6% | NBIX higher |
| ROE as of 2026-08-02 | -44.0% | +21.1% | NBIX higher |
| ROA as of 2026-08-02 | -39.6% | +14.7% | NBIX higher |
| Debt / equity as of 2026-08-02 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-08-02 | +2277.5% | +34.4% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +24.3% | |
| Beta as of 2026-08-02 | 1.10 | 0.39 | |
| 1-year return as of 2026-07-31 close | +192.1% | +33.5% | CRNX higher |
Fundamentals: market data, as of 2026-08-02. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.